Today the whole world is worried about the rising outbreak of Corona, this is a disease that shook from the poor to the rich, from common man to politicians, not only this, many people have lost their lives due to this disease. The wounds of corona are not yet healed and the third wave is ready to come, so it becomes the responsibility of all of us to get the vaccine as soon as possible, but the question comes in our mind that after all which vaccine is the most effective and Which vaccine should we get? Don’t worry, today we will answer to all your questions. Amid the rise in coronavirus cases, the race to develop a vaccine is on across the world. While a specific vaccine can take years to develop, drugmakers are aiming to bring a COVID-19 vaccine to market within a year of the outbreak. According to the World Health Organization (WHO), there are currently around 150 coronavirus vaccines in development globally.
According to the Vaccine Landscape document prepared by WHO, the top five candidates currently in the race are the frontrunners. The current pandemic of COVID-19 spread rapidly all over the world and had a devastating impact on all sectors of the economy. The impact of the COVID-19 pandemic was very severe as even developed countries such as the US, China, UK and Canada suffered heavy losses. However, the developed world wasted no time in developing a COVID-19 vaccine. The United States and China, Britain and Canada were able to develop and deploy a COVID-19 vaccine within 1.5 years of the pandemic, and have the fastest vaccines to date for the virus.
This is a remarkable achievement of medical science, as medical companies across the world have identified a new pathogen for the novel coronavirus known as the SARS-CoV-2 virus, in a bid to discover an immune response against it. To develop and test a safe and effective vaccine for Its in less than 12 months. Governments and drug administrators called Pfizer Inc., Moderna, Inc. and Johnson & Johnson were granted emergency authorization in less than a year, which is also a record. Several efforts are underway to help with the production and distribution of the COVID-19 vaccine more quickly. According to World Health Organization guidelines, each vaccine has to go through a three-stage clinical trial process before it can be legally authorized.
Top 5 vaccine to get :
• AZD1222 of Oxford University and AstraZeneca, United Kingdom
Developed by Oxford University and AstraZeneca, AZD1222 is in Phase 3 of human trials. In India, the vaccine will be produced by Serum Institute of India (SII), Pune and will be known as Covishield in the country. SII has also started clinical trial of Covishield in the country. Researchers working on AZD1222 have claimed that the vaccine is capable of producing positive results without or with mild side-effects.
• Moderna’s mRNA-1273, United States Of America
Vaccine candidate mRNA-1273 has been developed by biotech firm Moderna along with investigators from the US NIH (National Institute of Health). Data from the trial showed that participants appeared to produce an immune response similar to the one seen in those who have recovered from coronavirus infection.
• BioNTech, Fosub Pharma And Pfizer’s BNT162b1, Germany
Developed by biotechnology and pharmaceutical companies BioNTech, Fosub Pharma And Pfizer, vaccine candidate BNT162b1 is in the Phase 3 of human trials. The developers claim that in the earlier phases, the vaccine candidate has produced neutralizing antibodies and exhibited moderate side-effects like pain at the injection site, fatigue, headache, chills, muscle and joint pain, fever.
• CanSino Biological Inc./Beijing Institute Of Biotechnology’s Adenovirus Type 5 Vector, China
CanSino’s vaccine, has also been successful in producing antibody and T-cell immune responses and has not prompted any serious side-effects. After showing positive results, the vaccine is undergoing Phase 3 trials.
• Sinovac’s CoronaVac, China
Developed by Sinovac Biotech, coronavirus vaccine candidate CoronaVac is in Phase 3 clinical trials. The vaccine candidate has been approved for emergency use in China as part of a programme in the country to vaccinate high-risk groups such as medical staff.